Table 3.
Prescription characteristics and clotting predictors of continuous renal replacement therapy sessions.
| Parameter | Total (n = 101) | No clotting (n = 42) | Clotting (n = 59) | HR [95% CI] | P |
|---|---|---|---|---|---|
| Treatment modality | 0.059 | ||||
| CVVHD | 16 (15.8%) | 3 (18.8%) | 13 (81.2%) | Ref. | |
| CVVHDF | 84 (83.2%) | 39 (47.0%) | 45 (53.0%) | 0.50 [0.27–0.94] | 0.031 |
| SCUF | 1 (1.0%) | 0 (0.0%) | 1 (100.0%) | 1.64 [0.21–12.76] | 0.635 |
| Filter type | 0.033 | ||||
| HF1000 | 4 (4.0%) | 0 (0.0%) | 4 (100.0%) | Ref. | |
| HF20 | 14 (13.9%) | 4 (28.6%) | 10 (71.4%) | 1.47 [0.46–4.71] | 0.520 |
| M60 | 16 (15.8%) | 8 (50.0%) | 8 (50.0%) | 0.53 [0.16–1.78] | 0.304 |
| ST60 | 39 (38.6%) | 16 (41.0%) | 23 (59.0%) | 0.65 [0.22–1.91] | 0.437 |
| ST100 | 15 (14.9%) | 10 (66.7%) | 5 (33.3%) | 0.28 [0.07–1.07] | 0.063 |
| ST150 | 6 (5.9%) | 3 (50.0%) | 3 (50.0%) | 0.35 [0.07–1.56] | 0.168 |
| SEPTEX | 7 (6.9%) | 1 (14.3%) | 6 (85.7%) | 1.26 [0.36–4.49] | 0.718 |
| Membrane type | 0.005 | ||||
| PAES | 18 (17.8%) | 4 (22.2%) | 14 (77.8%) | Ref. | |
| AN69ST | 76 (75.2%) | 37 (48.7%) | 39 (51.3%) | 0.39 [0.21–0.74] | 0.004 |
| PAES-HCO | 7 (6.9%) | 1 (14.3%) | 6 (85.7%) | 0.98 [0.38–2.56] | 0.969 |
| Filter area | 0.030 | ||||
| 0.2 m2 | 14 (13.8%) | 4 (28.6%) | 10 (71.4%) | Ref. | |
| 0.6 m2 | 55 (54.5%) | 24 (43.6%) | 31 (56.4%) | 0.43 [0.21–0.88] | 0.022 |
| ≥ 1 m2 | 32 (31.7%) | 14 (43.6%) | 18 (56.4%) | 0.36 [0.16–0.79] | 0.010 |
| Prescription flows | |||||
| Blood flow (ml/min) | 60 [40–80] | 60 [50–100] | 60 [40–80] | 0.99 [0.99–1.00] | 0.379 |
| Dialysate flow (ml/h) | 400 [200–600] | 400 [250–500] | 400 [100–800] | 1.00 [1.00–1.00] | 0.073 |
| Replacement flow (ml/h) | 200 [50–400] | 200 [50–500] | 200 [0–400] | 0.99 [0.99–1.00] | 0.309 |
| Net ultrafiltration (ml /h) | 40 [25–70] | 40 [25–60] | 40 [25–70] | 1.00 [0.99–1.00] | 0.726 |
| Effluent flow (ml /h) | 900 [510–1120] | 790 [525–1080] | 910 [390–1130] | 1.00 [0.99–1.00] | 0.739 |
| Filtration fraction (%) | 17.1 [9.1–23.8] | 15.6 [5.7–22.4] | 18.7 [11.3–23.9] | 1.00 [0.98–1.03] | 0.849 |
| Vascular access site | 0.175 | ||||
| Jugular | 29 (28.7%) | 18 (62.1%) | 11 (37.9%) | Ref. | |
| Femoral | 55 (54.5%) | 20 (36.4%) | 35 (63.6%) | 1.51 [0.76–2.97] | 0.238 |
| ECMO | 17 (16.8%) | 4 (23.5%) | 13 (76.5%) | 2.16 [0.96–4.82] | 0.062 |
| Vascular access caliber | 8.0 [8.0–8.5] | 0.004 | |||
| ≤ 8 Fr | 65/92 (70.7%) | 24 (36.9%) | 41 (63.1%) | Ref. | |
| > 8 Fr | 27/92 (29.3%) | 16 (59.3%) | 11 (40.7%) | 0.37 [0.19–0.72] | |
| Vascular access length | 12.0 [11.5–14.0] | 0.806 | |||
| ≤ 12 cm | 46/71 (64.8%) | 22 (47.8%) | 24 (52.2%) | Ref. | |
| > 12 cm | 25/71 (35.2%) | 10 (40.0%) | 15 (60.0%) | 0.92 [0.48–1.76] | |
| Anticoagulation | 0.010 | ||||
| None | 18 (17.8%) | 5 (27.8%) | 13 (72.2%) | Ref. | |
| Heparin | 72 (71.3%) | 28 (39.4%) | 44 (60.6%) | 0.75 [0.40–1.40] | 0.376 |
| Citrate | 11 (10.9%) | 9 (81.8%) | 2 (18.2%) | 0.13 [0.03–0.59] | 0.008 |
AN69ST, acrylonitrile and sodium methallyl sulfonate copolymer; CVVHD(F), continuous veno-venous hemodialysis (Hemodiafiltration); HCO, high cut-off; HR, hazard ratio; PAES, polyarylethersulfone; Ref., reference; SCUF, slow continuous ultrafiltration.